《大行報告》野村下調威高股份(01066.HK)目標價至11.87元 評級「買入」
野村發表研究報告,預測威高股份(01066.HK)上半年收入將按年增長8.1%,達到67億元人民幣,較市場預期低約3%,並預期淨利潤將增長6.1%至14億元人民幣。
該行解釋,主要由於疫情打亂3月至4月份的產品交付,以及帶量採購減緩其骨科產品的增長。該行預測,上半年臨牀護理產品收入增長5%,達到22億元人民幣;醫藥包裝產品收入料達11億元人民幣,增長18%;骨科產品收入增長5%至11億元人民幣;介入產品收入增長10%至9.52億元。
由於產品結構改變,野村預期威高上半年毛利率將下降約2.8個百分點至56%,維持「買入」評級,同時將目標價由12.26元輕微下調至11.87元。野村亦今明兩年收入預測分別下調2%及3%,並將明年淨利潤預測下調1%,以反映疫情影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.